Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 18;133(16):1715-1719.
doi: 10.1182/blood-2018-12-852376. Epub 2019 Feb 22.

Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL

Emily Curran  1 , Wendy Stock  1
Affiliations
Review

Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL

Emily Curran et al. Blood. .

Abstract

Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: E.C. received research funding from Gilead Sciences and Merck, received research funding from Incyte, and served on the advisory board for Shire. W.S. served on the advisory board for Amgen, Pfizer, Astellas, Gilead/Kite, Agios, Jazz, received royalties from Up to Date, and received honoraria from Research to Practice.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Challenges of blinatumomab for MRD in ALL. Decreasing levels of MRD with increasing ratio of effector T cells (orange) to leukemia cells (blue). Regulatory T cells are indicated in purple.
See this image and copyright information in PMC

References

    1. Bassan R. Toward victory in adult ALL: blinatumomab joins in. Blood. 2012;120(26):5094-5095. - PubMed
    1. Przepiorka D, Ko CW, Deisseroth A, et al. . FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035-4039. - PubMed
    1. Topp MS, Gökbuget N, Stein AS, et al. . Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57-66. - PubMed
    1. Kantarjian H, Stein A, Gökbuget N, et al. . Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847. - PMC - PubMed
    1. Martinelli G, Boissel N, Chevallier P, et al. . Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795-1802. - PubMed

Publication types

MeSH terms